BioXcell热销产品--RecombiMAb anti-mouse PD-1 (CD279) (D265A)
产品描述：
RMP1-14-CP002单克隆抗体是原始RMP1-14克隆号的重组嵌合型抗体。可变结构域序列与原始RMP1-14克隆号相同，但是恒定区序列已经从大鼠IgG2a变为小鼠IgG1。RMP1-14-CP002单克隆抗体在Fc片段中也含有D265A突变，使其无法与内源性Fcγ受体结合。
RMP1-14-CP002单克隆抗体与小鼠PD-1（程序性死亡-1蛋白，也称为CD279）反应。PD-1是一种50-55 kDa的细胞表面受体，由Pdcd1基因编码，属于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上瞬时表达。成功清除抗原后，PD-1表达下降。此外，Pdcd1 mRNA在前B细胞阶段在发育中的B淋巴细胞中表达。PD-1的结构包括一个ITIM(免疫受体酪氨酸抑制基序),表明PD-1负调节TCR信号。PD-1通过结合它的两个配体PD-L1和PD-L2发出信号，这两个配体都是B7家族的成员。配体结合后，PD-1信号抑制T细胞活化，导致增殖、细胞因子产生和T细胞死亡减少。此外，已知PD-1在小鼠的外周耐受性和预防自身免疫性疾病中起关键作用，因为PD-1敲除动物表现出扩张性心肌病、脾肿大和外周耐受性丧失。诱导的PD-L1表达常见于许多肿瘤，包括鳞状细胞癌、结肠腺癌和乳腺腺癌。PD-L1过度表达导致肿瘤细胞对CD8 T细胞介导的裂解的抗性增加。在黑色素瘤的小鼠模型中，通过用阻断PD-L1和它的受体PD-1之间的相互作用的抗体治疗，肿瘤生长可以暂时被抑制。目前PD-1是免疫疗法作为癌症治疗的热门靶点之一。
产品详情：
产品名称 | |
产品货号 | |
产品规格 | 1mg |
反应种属 | Mouse |
克隆号 | RMP1-14-CP002 |
同种型 | Mouse IgG1(switched from rat IgG2a) |
免疫原 | Syrian Hamster BKH cells transfected with mouse PD-1 cDNA |
实验应用 | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody |
产品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
纯度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
无菌处理 | 0.2 µm filtration |
纯化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原检测 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存条件 | 抗体原液保存在4°C，不能冷冻保存。 |
推荐抗体稀释液 | InVivoPure pH 7.0 Dilution Buffer（货号IP0070） |
该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：
应用 | 文章 |
体内PD-1/PD-L信号阻断 (in vivo blocking of PD-1/PD-L signaling) | 1. Triplett, T. A., et al. (2018). 'Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme' Nat Biotechnol 36(8): 758-764.
2. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 3. Moynihan, K. D., et al. (2016). 'Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses' Nat Med. doi : 10.1038/nm.4200.
4. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.
5. Evans, E. E., et al. (2015). 'Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies' Cancer Immunol Res 3(6): 689-701.
6. Zelenay, S., et al. (2015). 'Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity' Cell 162(6): 1257-1270.
7. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. |
更多产品详情请咨询 BioXCell 中国授权代理——欣博盛生物
全国服务热线: 4006-800-892 邮箱: market@hnyazd.com
深圳: 0755-26755892 北京: 010-88594029
广州：020-87615159 上海: 021-34613729
代理品牌网站: www.hnyazd.com
自主品牌网站: www.neobiosescience.net
